Advertisement

Topics

Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

02:00 EDT 18 May 2017 | InvestorIdeas

May 18, 2017 (Investorideas.com Newswire) In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program.

Original Article: Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

NEXT ARTICLE

More From BioPortfolio on "Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug"

Quick Search
Advertisement